Progress in Gene Therapy for Prostate Cancer by Kamran A. Ahmed et al.
REVIEW ARTICLE
published: 19 November 2012
doi: 10.3389/fonc.2012.00172
Progress in gene therapy for prostate cancer
Kamran A. Ahmed 1, Brian J. Davis1*,Torrence M.Wilson2, Gregory A.Wiseman3, Mark J. Federspiel 4 and
John C. Morris5
1 Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
2 Department of Urology, Mayo Clinic, Rochester, MN, USA
3 Division of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA
4 Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA
5 Division of Endocrinology, Mayo Clinic, Rochester, MN, USA
Edited by:
Jean-Pierre Pouget, INSERM, France
Reviewed by:
Joel S. Greenberger, University of
Pittsburgh Medical Center-Shadyside,
USA
Michael W. Epperly, University of
Pittsburgh Cancer Institute, USA
*Correspondence:
Brian J. Davis, Department of
Radiation Oncology, Mayo Clinic, 200
First Street SW, Rochester, MN
55905, USA.
e-mail: davis.brian@mayo.edu
Gene therapy has held promise to correct various disease processes. Prostate cancer rep-
resents the second leading cause of cancer death in American men. A number of clinical
trials involving gene therapy for the treatment of prostate cancer have been reported. The
ability to efficiently transduce tumors with effective levels of therapeutic genes has been
identified as a fundamental barrier to effective cancer gene therapy. The approach utilizing
gene therapy in prostate cancer patients at our institution attempts to address this defi-
ciency.The sodium-iodide symporter (NIS) is responsible for the ability of the thyroid gland
to transport and concentrate iodide. The characteristics of the NIS gene suggest that it
could represent an ideal therapeutic gene for cancer therapy. Published results from Mayo
Clinic researchers have indicated several important successes with the use of the NIS
gene and prostate gene therapy. Studies have demonstrated that transfer of the human
NIS gene into prostate cancer using adenovirus vectors in vitro and in vivo results in effi-
cient uptake of radioactive iodine and significant tumor growth delay with prolongation of
survival. Preclinical successes have culminated in the opening of a phase I trial for patients
with advanced prostate disease which is currently accruing patients. Further study will
reveal the clinical promise of NIS gene therapy in the treatment of prostate as well as
other malignancies.
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GENE THERAPY
Gene therapy was first conceptualized in 1972 with the promise
to correct numerous inheritable diseases. Gene therapy functions
by using DNA packaged into a vector to insert itself into a human
genome and alter the cell in a manner designed to preserve the
overall health and life of the organism (Friedmann and Rob-
lin, 1972). By encoding a therapeutic protein, a host of diseases
could potentially be treated. Many of the first potential targets
for gene therapy were considered to be hematopoietic disorders
in which the mechanism of disease was well understood. In these
disorders, cells could often be easily manipulated in the labora-
tory setting (Anderson, 1984). Unfortunately, many of the early
promises of gene therapy were dampened by technical challenges
involved with gene transfer in high numbers of hematopoietic
stem cells and high levels of β-globin gene expression in erythro-
cytes. Attention then turned to the promise of gene therapy being
used in the treatment of severe combined immunodeficiency dis-
order (SCID). The use of gene therapy with SCID was filled with
both successes and failures until one of the major breakthroughs
reported in 2000 by Cavazzana-Calvo et al. (2000). This group
demonstrated immune reconstitution in five infants with X-linked
SCID who underwent gene therapy. This was then followed by
Aiuti et al. (2002) describing initial signs of immune reconstitution
in two infants with SCID due to adenosine deaminase deficiency
(ADA).
Since that time other successes have been reported with the use
of gene therapy in adrenoleukodystrophy (Cartier and Aubourg,
2010), Parkinson’s disease (LeWitt et al., 2011), and the retinal
disease, Leber’s Congenital Amaurosis (Bainbridge et al., 2008;
Cideciyan et al., 2009). These triumphs have renewed the promise
of gene therapy in the fight against various disease processes. How-
ever, there has been limited success in the use of gene therapy
to combat cancer. Although gene therapy approaches have been
developed for numerous malignancies, clinical trials completed to
date have fallen short of expectations (Humphreys et al., 1999;
Hung et al., 2000; Cascallo et al., 2003; Miura et al., 2005; Young
et al., 2006). However, one of several areas of progress includes
the use of viruses capable of replicating selectively in cancer cells.
These oncolytic viruses provide an opportunity to attack a number
of mechanistically distinct cellular pathways while also generating
progeny viruses capable of spreading throughout a tumor mass
(Chiocca, 2002; Ries and Brandts, 2004). In China, gene therapy
has been licensed as a regular treatment for head and neck cancer,
using an adenovirus (ADV) to deliver the p53 tumor suppressor
gene by direct injection into the tumor given in combination with
radiotherapy (Peng, 2005).
GENE THERAPY IN PROSTATE CANCER
Prostate cancer represents the second leading cause of cancer death
in American men (Ruijter et al., 1999). The majority of men
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present with curable and localized disease, yet approximately 30%
of patients will progress to advanced stages within 10–15 years
of diagnosis. Metastatic prostate cancer may have a long course,
but it is almost invariably incurable. Typically, systemic hormonal
options, such as chronic androgen deprivation therapy (ADT),
are initiated when metastatic disease is diagnosed. ADT provides
cancer control and palliation for variable periods of time ranging
from a few months to several years. For men who progress to the
hormone refractory state, treatment with docetaxel chemotherapy
is an option (Tannock et al., 2004). At the present time, there is no
standard treatment for patients with progressive disease following
docetaxel chemotherapy. Metastatic, androgen resistant prostate
cancer remains a leading cause of death in American men. For this
reason, novel strategies, including those involving gene therapy,
are needed.
A number of clinical trials involving gene therapy for the
treatment of prostate cancer are ongoing and a few have been
completed. These trials are summarized in Table 1. In several clin-
ical trials ADV was injected directly into the prostate. These studies
have utilized several transgenes, including p53, Herpes simplex tk,
IL-2, IL-12, and RVTP1. In the first reported results of 18 patients
with locally recurrent prostate cancer, a single dose, dose esca-
lation study was conducted using an ADV vector with the HSV
thymidine kinase gene (Adv/HSV-tk) injected transrectally into
one lobe of the prostate followed by ganciclovir (GCV; Herman
et al., 1999). There was no local toxicity; the most common adverse
events reported were liver transaminase elevations (three Grade
1 and one Grade 4), fever, thrombocytopenia, and leukopenia.
In another multiple-dose, dose escalation study, RPR/ING/N201,
a replication-defective ADV with a wild type p53 was injected
intraprostatically in 17 patients with locally advanced disease every
2 weeks for a total of up to three treatments prior to radical prosta-
tectomy (RP; Sweeney and Pisters, 2000). Only mild toxicities were
reported.
CV706 is a prostate-specific antigen (PSA)-selective, replication-
competent ADV that has been shown to selectively kill human
prostate cancer xenografts in preclinical models (Rodriguez et al.,
1997). A phase I study for the treatment of patients with locally
recurrent prostate cancer after radiation therapy was conducted
(DeWeese et al., 2001). Twenty patients in five groups were treated
with doses ranging from 1× 1011 to 1× 1013 viral particles (vp)
delivered by a transrectal ultrasound-guided transperineal tech-
nique using a three-dimensional plan. The primary end point was
the determination of treatment-related toxicity. The study found
CV706 to be safe and not associated with irreversible grade 3 or 4
toxicity. No grade >1 alterations in liver function tests associated
with CV706 administration were reported.
A phase I dose escalation clinical trial conducted at Baylor Col-
lege of Medicine (Herman et al., 1999) of intraprostatic injection
of a replication-deficient ADV containing the herpes simplex virus
thymidine kinase gene (HSV- tk), followed by intravenous admin-
istration of the prodrug GCV, was conducted. One patient at the
Table 1 | Prostate cancer gene therapy trials.
Strategy Investigator Date Institution
Cytokine (GM-CSF) immunotherapy (ex vivo) Simmons Aug-94 Johns Hopkins
Cytokine (GM-CSF) allogeneic immunotherapy (ex vivo) Simmons Sep-97 Johns Hopkins
Retrovirus antisense c-myc Steiner Sep-95 Vanderbilt
Intradermal vaccinia-PSA Chen Sep-95 Naval Medical Academy
Adenovirus ganciclovir/TK Scardino Jan-96 Baylor
Intradermal vaccinia-PSA Kufe Sep-96 Dana Farber
Intradermal vaccinia-PSA Sanda May-97 University of Michigan
Liposome IL-2 Belldegrun Belldegrun May-97 UCLA
Adenovirus ganciclovir/TK Hall Feb-98 Mt. Sinai Hospital
Adenovirus p53 Belldegrun Belldegrun Sep-97 UCLA
Adenovirus p53 Logothetis Logothetis Nov-97 MD Anderson
Adenovirus ganciclovir/TK Kadmon Feb-98 Baylor
Intramuscular vaccinia MUC-1-IL-2 Figlin May-98 UCLA
Adenovirus, prostate oncolytic Simons Jun-98 Johns Hopkins
Adenovirus, IL-12 Miles Jun-98 Baylor
Adenovirus, IL-12 Belldegrun Nov-00 UCLA
Adenovirus, IL-12 Hall Apr-05 Mt. Sinai Hospital
Adenovirus RVTP1 Kadmon Aug-06 Baylor
Replicating Ad+EBRT Movasis Dec-07 Henry Ford Hospital
Adenovirus, valacyclovir Shirakawa Dec-07 Kobe University, Japan
Adenovirus (NTR) Patel Jul-09 CR UK Institute for Cancer Studies
Adenovirus (NTR), prodrug CB1954 Onion Nov-09 CR UK Institute for Cancer Studies
Replicating Ad (hNIS) Barton Jul-11 Henry Ford Hospital
Adenovirus (GLIPR1) Sonpavde Nov-11 Baylor
EBRT, External beam radiotherapy; GLIPR1, Glioma pathogenesis-related protein 1; GM-CSF, Granulocyte macrophage colony stimulating factor; hNIS, Human iodide
symporter; IL, Interleukin; NTR, Nitro reductase; PSA, Prostate-specific antigen; TK, Thymidine kinase.
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highest dose level developed an objective response, one each at
the three highest dose levels, documented by a fall in serum PSA
levels by 50% or more, sustained for 6 weeks to 1 year. This study is
reported to be the first to demonstrate anticancer activity of gene
therapy in patients with prostate cancer.
A phase I study of replication-competent ADV-mediated gene
therapy for locally recurrent prostate cancer involving delivery of
two suicide genes, cytosine deaminase and HSV-tk, was the first
study reporting injection of replicating ADV in humans (Freytag
et al., 2002). Sixteen patients were studied with a maximum viral
dose of 1012 vp. No dose limiting toxicities were observed and
the maximum tolerated dose (MTD) was not defined. A total of
7 of 16 patients demonstrated>25% fall in PSA and two patients
are negative for prostate cancer as determined by prostate biopsy
after 1 year. This same vector was used in two additional trials
combining gene therapy with chemotherapy and radiation, both
demonstrating low toxicities, no dose limiting toxicity (DLT) and
declines in PSA levels, although the responses were short term in
both trials (Freytag et al., 2003, 2007).
A phase I/II clinical trial from the United Kingdom by Patel et al.
(2009) reported on direct intraprostatic injection of a defective
ADV vector (CTL102) encoding bacterial nitroreductase (NTR)
in conjunction with a systemic prodrug. The cohort of patients
were split into two groups; one group scheduled for RP received
the virus alone, in a dose escalation study to establish toler-
ability, safety, and expression of NTR. To establish safety and
tolerability, a second group of 19 patients with local failure fol-
lowing primary treatment received virus plus prodrug. A total
of 14 of these patients had a repeat treatment. Results indicated
minimal toxicity and preliminary evidence of a change in PSA
kinetics.
Recently, Sonpavde et al. (2011) conducted a phase I clini-
cal trial to evaluate the safety and activity of the neoadjuvant
intraprostatic injection of ADV expressing the tumor suppres-
sor gene GLIPR1 for intermediate or high-risk prostate cancer
before RP. Nineteen patients received a single injection into the
prostate followed 4 weeks later by RP using six vp dose levels.
Toxicities included urinary tract infection (n= 3), flu-like syn-
drome (n= 3), fever (n= 1), dysuria (n= 1), and photophobia
(n= 1). Results indicated biologic antitumor activity and systemic
immune responses.
In spite of these initial encouraging results, an optimal gene
therapy strategy in prostate cancer has yet to be determined.
Effective approaches to gene therapy depend on the ability to
deliver therapeutic genes to target cells. The ability to efficiently
transduce tumors with effective levels of therapeutic genes has
been identified as a fundamental barrier to effective cancer gene
therapy (Herrmann, 1995; Waehler et al., 2007). To address this
issue, conditionally replicating viruses, including the ADV, have
been constructed and their efficacy has been evaluated (Mark-
ert et al., 1993; Bischoff et al., 1996; Russell, 2002). It is sug-
gested from previous gene therapy trials in cancer patients that
a multimodality approach utilizing chemotherapy and/or radio-
therapy may be required in order to maximize efficacy (Chu
et al., 2004). The approach utilizing gene therapy in prostate
cancer patients at our institution attempts to address these two
deficiencies.
PROSTATE CANCER GENE THERAPY WITH THE
SODIUM-IODIDE SYMPORTER (NIS)
Radioactive iodine (131I) is one of the most effective forms of
systemic radiotherapy available today (Mazzaferri and Kloos,
2001). Even in advanced cases, thyroid cancer can be effectively
treated by radioactive iodine therapy. Radioiodine has great util-
ity in the management of thyroid cancer because thyroid cells
possess the ability to concentrate iodide from extracellular fluid.
This iodine trapping activity of thyroidal cells is utilized both in
the diagnosis as well as treatment of thyroid cancer. Function-
ing thyroid cancer metastases can be detected by administering
radioiodine in the form of 123I and then imaging with a gamma
camera. Metastases that are imaged by this technique are then tar-
geted for therapy by administration of therapeutic doses of 131I to
the patient. The success rate of metastatic thyroid cancer treated
with 131I is reflected in the low mortality of patients suffering from
the disease. This is also true for patients with advanced disease and
diffuse pulmonary metastases at initial presentation who can be
successfully treated by 131I, achieving a 10 year survival rate of over
80% (Mazzaferri and Jhiang, 1994).
The sodium-iodide symporter (NIS) is an intrinsic membrane
glycoprotein, with 13 transmembrane domains, which is responsi-
ble for the ability of the thyroid gland to transport and concentrate
iodide (Figure 1). TSH-regulated NIS expression is specific for thy-
roid cells, whereas many other organs which lack NIS expression,
including the prostate gland, do not concentrate iodide (Spitzweg
et al., 1999). Cloning and characterization of the human NIS
(hNIS) gene offers the possibility to deliver the gene into non-
thyroid cells, thereby allowing those non-thyroidal cells to trap
radioiodine. Mayo Clinic researchers have extensively explored the
possibility of using this gene as a therapeutic for numerous types
of cancers. In addition, other groups have investigated the use of
the NIS gene as a therapeutic in breast (Tazebay et al., 2000), brain
(Cho et al., 2000), and liver (Haberkorn, 2001) cancers.
Animal studies have demonstrated that expression of the hNIS
gene by plasmid or adenoviral mediated gene transfer in prostate
cancer cells results in a large concentration of iodide by the cells
(Markert et al., 1993) as visualized in the mouse model depicted
in Figure 2. Uptake is of sufficient magnitude and duration in vivo
that administration of therapeutic doses of 131I to animals bear-
ing prostate cancer xenografts results in highly effective therapy of
those tumors, achieving complete response rates as high as 80%
(Spitzweg et al., 2001).
The characteristics of the NIS gene suggest that it could repre-
sent an ideal therapeutic gene for cancer therapy, having several
advantages over other investigated genes. Most importantly is its
high degree of efficacy. NIS is already a therapeutic gene in that
its native expression in thyroid cells is used for therapy of thyroid
cancer and hyperthyroidism (Mazzaferri, 1996). It also has a high
bystander effect where 131I decay, which occurs primarily through
emission of β particles that traverse up to 2 mm within the tissue,
allows the energy of the decay to be deposited into cells that are
neighbors of the cell in which the event occurred. Thus, not every
cell must be transfected and express NIS to be effected by radioio-
dine therapy. This is important for any cancer gene therapy strat-
egy because of the difficulty in achieving 100% transfection with
the therapeutic gene. NIS is a normal human gene and protein,
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FIGURE 1 | Structure of the human sodium-iodide symporter (hNIS).
FIGURE 2 | 123I scan of a mouse with the adenovirus-derived vector
with a non-specific promoter (CMV) carrying the sodium-iodide
symporter gene (NIS; Ad-CMV-NIS). The infected prostate cancer
xenograft over right hip shows radioiodine uptake while there is no uptake
over the control tumor on the left hip.
which means its expression in cancer cells is unlikely to be toxic or
limit its efficacy in patients. Because expression of NIS is not toxic
to the cells in the absence of radioiodine, no special techniques to
avoid killing of virus producing cells are required for generation of
the viral vectors. Thus, production of vectors only utilizes standard
techniques. Furthermore, NIS has a high specificity. Although NIS
is a normally expressed human gene, its native expression is con-
fined only to a small number of organs, including the thyroid,
where its expression is highest. Therefore, the uptake of radioio-
dine in these organs does not cause significant morbidity outside
the intended organ of interest. This strategy protects normal tis-
sues while targeting the site of treatment in the prostate. Lastly, in
contrast to other currently used therapeutic genes, NIS expression
can be directly monitored and quantified non-invasively using
radioiodine scanning and nuclear medicine techniques.
PROGRESS AT THE MAYO CLINIC
Published results from Mayo Clinic researchers have indicated sev-
eral important successes with the use of the NIS gene and prostate
gene therapy. It has been demonstrated that transfer of the hNIS
gene into prostate cancer using ADV vectors in vitro and in vivo
results in highly efficient uptake of radioactive iodine (Spitzweg
et al., 1999). This was also shown using a recombinant measles
virus derived from the Edmonston vaccine strain (MV-Edm).
Intratumoral administration of the virus resulted in statistically
significant tumor growth delay (P = 0.004) and prolongation of
survival (P = 0.001) in a subcutaneous xenograft model. Studies
have also shown that adenoviral constructs containing NIS used
to transfect prostate cancer xenografts demonstrated uptake of
radioiodine sufficient to induce tumor volume reduction up to
80% in comparison to control tumors after treatment with a sin-
gle dose of 131I (Spitzweg et al., 2001; Kakinuma et al., 2003).
This finding could be particularly useful for smaller tumors or
micrometastases.
Researchers at Mayo have also completed biotoxicity and
biodistribution studies in dogs, which revealed the successful
introduction of localized NIS expression in the prostate gland
with no vector-related toxicity observed. No animals experienced
any surgical complications, and laboratory panels showed no
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FIGURE 3 | Arrow A points to fiducial markers for external beam
radiotherapy image guidance, arrow B points to Foley catheter, and
arrow C to increased uptake of I-123 in the prostate attributable to
incorporation of the NIS gene in to prostate cells via in situ injections.
significant change following therapy providing further support
for the translation of this work to the clinical setting (Dwyer
et al., 2005). Our experience with ADV-mediated NIS transfer
and radioiodine therapy has been confirmed in large animal mod-
els, which has culminated in the opening of a phase I trial for
patients with advanced prostate disease. Patients in the study have
all experienced local recurrence following external beam radiation
treatment (http://clinicaltrials.gov/ct/show/NCT00788307). The
study is currently open and accruing patients. Figure 3 displays
the uptake of 131I in the prostate following NIS gene transfer.
This dose escalation trial will help determine how much
radioiodine can be safely injected to achieve the maximal ther-
apeutic effect. In thyroid cancer, radioiodine is administered in
a fixed dose regimen. The 2009 American Thyroid Association
guidelines recommend using the minimal activity necessary to
achieve successful ablation (between 30 and 100 mCi; Cooper
et al., 2009). NIS gene therapy has the potential for a signifi-
cant therapeutic effect with direct injection of the vector into the
prostate which permits concentration of radioiodine directly in the
prostate. However, preclinical animal models have demonstrated
some uptake of radioiodine in thyroid and gastric mucosa, which
may ultimately limit dose escalation and the achievable therapeutic
effect in patients (Dwyer et al., 2005). Further clinical study will
reveal the maximal dose necessary to achieve a therapeutic effect
while limiting toxicity.
FUTURE DIRECTIONS
As with many current treatment regimens for cancer, gene
therapy utilized as a monotherapy may not be the sole solu-
tion. A multimodal approach combining virus based gene ther-
apy with chemotherapy and/or radiotherapy may be neces-
sary for more complete tumor eradication. The development
of phase I trials using a multimodal approach to therapy will
likely be necessary once a gene therapy strategy has been opti-
mized.
Due to the technical aspects involved in the clinical application
of gene therapy, progress has been noted but there is much work
left to accomplish. Although the majority of our work to date has
utilized the prostate cancer model, researchers have also demon-
strated the utility of NIS mediated gene therapy in vitro and/or
in vivo for several other tumor models, including breast, pancreas,
colon, medullary thyroid, ovarian carcinomas (Scholz et al., 2005;
Dwyer et al., 2006a,b), and in multiple myeloma (Dingli et al.,
2004). Initial preclinical results appear promising; however, only
further study will reveal the clinical promise of NIS gene therapy
in these cancers.
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